Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 12, 2006, Pages 1472-1480

  Vanderstichele, Hugo ^a   De Vreese, Karen ^a   Blennow, Kaj ^b   Andreasen, Niels ^c   Sindic, Christian ^d   Ivanoiu, Adrian ^d   Hampel, Harald ^e   Bürger, Katharina ^e   Parnetti, Lucilla ^f   Lanari, Alessia ^f   Padovani, Allesandro ^g   DiLuca, Monica ^g   Bläser, Miriam ^a   Ohrfelt Olsson, Annika ^b   Pottel, Hans ^a   Hulstaert, Frank ^a   Vanmechelen, Eugeen ^a  

^a INNOGENETICS   (Belgium)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY OF PERUGIA   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Dementia; Diagnosis; P tau181P; Performance

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ACCURACY; ADULT; AGED; ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMENTIA WITH LEWY BODY; DISCRIMINANT ANALYSIS; FEMALE; HUMAN; LEWY BODY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PHOSPHO TAU ASSAY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; DISCRIMINANT ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEWY BODY DISEASE; LOGISTIC MODELS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHOTHREONINE; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 33845713197     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.258     Document Type: Article

References (30)

1. Wiltfang J, Esselman H, Maler JM, Bleich S, Hüther G, Kornhuber J. Molecular biology of Alzheimer's dementia and its clinical relevance to early diagnosis and new therapeutic strategies. Gerontology 2001;47:65-71.
2. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 2000;33:95-130.
3. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.
4. Consensus report of the working group on molecular and biochemical markers of Alzheimer's disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-16 (Erratum in Neurobiol Aging 1998;19:285).
5. Vanmechelen E, Van Kerschaver E, Blennow K, De Deyn PP, Galasko D, Parnetti L, et al. CSF-Phospho-tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies. In: Iqbal K, Sisodia SS, Winblad B, editors. Alzheimer's disease: advances in etiology, pathogenesis and therapeutics. New York: Wiley, 2001;285-91.
6. (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004;62:1580-4.
7. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989;3:519-26.
8. Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin J-J, et al. Detection of τ proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-34.
9. (1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-58.
10. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
11. ISO 5725-2: Accuracy (trueness and precision) of measurement methods and results - Part 2: Basic method for the determination of repeatability and reproducibility of a standard measurement method, Geneva: International Organization for Standardization, 1994.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
13. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
15. (1-42) and tau levels in CSF. Neurology 1999;52:1555-62.
16. Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J 1994;301:871-7.
17. Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:624-30.
18. 181) in cerebrospinal fluid by the xMAP Technology. Clin Chem 2005;51:336-45.
19. 1-40 in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 2006;44:192-5.
20. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004;1:213-25.
21. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004;61:95-102.
22. Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E, et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects - a comparative CSF study. Neurology 2005;65:1502-3.
23. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002;59:1267-72.
24. Nägga K, Gottfries J, Blennow K, Marcusson J. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 2002;14:183-90.
25. Jimenez-Jimenez FJ, Hernanz A, Medina-Acebron S, de Bustos F, Zurdo JM, Alonso H, et al. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2005;111:114-7.
26. Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 2003;8:343-7.
27. Zetterberg H, Blennow K. Elevated total tau/phospho-tau ratio in autopsy-proven Creutzfeldt-Jakob disease with negative 14-3-3 test results. Neurol Sci 2004;25:301-2.
28. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci 2004;23:115-22.
29. 42. Arch Neurol 2003;60:1202-6.
30. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, et al. Tau protein, Aβ42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005;19:164-70.